Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells

N/ACompletedNCT02090803

Institut de Cancérologie de la Loire189 enrolled

Overview

The purpose of this study is to assess the human herpes virus reactivation 6 post autologous stem cells in 196 patients. The aim of our study was to describe the incidence of reactivation of HHV-6 in patients requiring autologous HSCT and determine the pathogenic role in this target population.

Study Type

OBSERVATIONAL

Enrollment

189

Conditions

Hematologic Diseases

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * all patients hospitalized in the Hematology Clinic of Saint-Etienne and Clermont-Ferrand and receiving autologous hematopoietic stem cells, according to the decision of the Consultative Meeting Multidisciplinary service; * Autologous recipients are included irrespective of causal hemopathy (myeloma, lymphoma, acute leukemia, mainly). Exclusion Criteria: * The non-consenting patients or unable to give consent

Locations (3)

CHU Clermont-Ferrand

Clermont-Ferrand, France

HCL

Lyon, France

CHU Saint-Etienne - laboratoire de virologie

Saint-Etienne, France

Outcomes

Primary Outcomes

HHV-6 biological reactivation

HHV-6 biological reactivation (blood viral load) is defined by a detectable viral load HHV-6 and\> 450 copies / mL on two occasions one week apart.

Time frame: 40 days

Secondary Outcomes

Aplasia output or engraftment

Time frame: 40 days

Reconstitution of hematopoiesis

Time frame: 40 days

Disease HHV-6

Time frame: 40 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.